JANX Quote, Financials, Valuation and Earnings

Arvinas has a net margin of -6391.57% compared to Janux Therapeutics's net margin of -76.18%. Janux Therapeutics's return on equity of -11.37% beat Arvinas's return on equity of -32.96%.

Janux Therapeutics has a consensus price target of $85.33, signalling upside risk potential of 174.83%. On the other hand Arvinas has an analysts' consensus of $36.22 which suggests that it could grow by 300.25%. Given that Arvinas has higher upside potential than Janux Therapeutics, analysts believe Arvinas is more attractive than Janux Therapeutics.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arvinas has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.541%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Arvinas quarterly revenues of $59.2M. Janux Therapeutics's net income of -$20.2M is higher than Arvinas's net income of -$45.1M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 127.89x versus 2.47x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Fortress Biotech has a net margin of -6391.57% compared to Janux Therapeutics's net margin of -87.96%. Janux Therapeutics's return on equity of -11.37% beat Fortress Biotech's return on equity of --.

Janux Therapeutics has a consensus price target of $85.33, signalling upside risk potential of 174.83%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 834.96%. Given that Fortress Biotech has higher upside potential than Janux Therapeutics, analysts believe Fortress Biotech is more attractive than Janux Therapeutics.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.825, suggesting its more volatile than the S&P 500 by 82.547%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Janux Therapeutics's net income of -$20.2M is lower than Fortress Biotech's net income of -$12.9M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 127.89x versus 0.46x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Hepion Pharmaceuticals has a net margin of -6391.57% compared to Janux Therapeutics's net margin of --. Janux Therapeutics's return on equity of -11.37% beat Hepion Pharmaceuticals's return on equity of --.

Janux Therapeutics has a consensus price target of $85.33, signalling upside risk potential of 174.83%. On the other hand Hepion Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 521639.13%. Given that Hepion Pharmaceuticals has higher upside potential than Janux Therapeutics, analysts believe Hepion Pharmaceuticals is more attractive than Janux Therapeutics.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hepion Pharmaceuticals has a beta of 1.794, suggesting its more volatile than the S&P 500 by 79.389%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hepion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Hepion Pharmaceuticals pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are larger than Hepion Pharmaceuticals quarterly revenues of --. Janux Therapeutics's net income of -$20.2M is lower than Hepion Pharmaceuticals's net income of -$4.9M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Hepion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 127.89x versus -- for Hepion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Innoviva has a net margin of -6391.57% compared to Janux Therapeutics's net margin of 22.15%. Janux Therapeutics's return on equity of -11.37% beat Innoviva's return on equity of 3.44%.

Janux Therapeutics has a consensus price target of $85.33, signalling upside risk potential of 174.83%. On the other hand Innoviva has an analysts' consensus of $19.00 which suggests that it could grow by 4.17%. Given that Janux Therapeutics has higher upside potential than Innoviva, analysts believe Janux Therapeutics is more attractive than Innoviva.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innoviva has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.553%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Innoviva pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Innoviva quarterly revenues of $91.8M. Janux Therapeutics's net income of -$20.2M is lower than Innoviva's net income of $20.3M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Innoviva's PE ratio is 96.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 127.89x versus 4.04x for Innoviva. Usually stocks with elevated PS ratios are considered overvalued.